

This listing of claims will replace all prior versions, and listings, of claims in the application.

**I. Listing of Claims:**

- Sub C1*
- B1*
1. (Canceled)
  2. (Canceled)
  3. (Canceled)
  4. (Canceled)
  5. (Canceled)
  6. (Canceled)
  7. (Canceled)
  8. (Canceled)
  9. (Canceled)
  10. (Canceled)
  11. (Canceled)
  12. (Canceled)
  13. (Canceled)
  14. (Canceled)
  15. (Canceled)

**DOCKET NO.:** ARC2865N1  
**Application No.:** 09/802,709

**PATENT**

- Sub C1*
- B1 cont.*
16. ~~(Canceled)~~
  17. ~~(Canceled)~~
  18. ~~(Canceled)~~
  19. ~~(Canceled)~~
  20. ~~(Canceled)~~
  21. ~~(Canceled)~~
  22. ~~(Canceled)~~
  23. ~~(Canceled)~~
  24. ~~(Canceled)~~
  25. ~~(Canceled)~~
  26. ~~(Canceled)~~
  27. ~~(Canceled)~~
  28. ~~(Canceled)~~
  29. ~~(Canceled)~~
  30. ~~(Canceled)~~
  31. ~~(Canceled)~~
  32. ~~(Canceled)~~

33. (Canceled)

34. (Canceled)

35. (Canceled)

36. (Canceled)

37. (Currently amended) A method for treating Attention-Deficit Disorder or Attention-Deficit Hyperactivity Disorder in a patient, wherein the method comprises administering a pharmaceutically acceptable composition comprising 100 ng to 500 mg of methylphenidate a member selected from the group consisting of amphetamine, dextroamphetamine, methamphetamine, phenylisopropylamine, pemoline, and a pharmaceutically acceptable carrier to said patient in a manner that achieves a substantially ascending methylphenidate plasma drug concentration over a time period of about 5.5 hours following said administration, in a sustained and increasing dose for treating Attention-Deficit Disorder in the patient.

38. (Canceled)

39. (Canceled)

40. (Canceled)

41. (Canceled)

42. (Canceled)

43. (Canceled)

44. (Canceled)

45. (Canceled)

Sub C1  
46. (new) The method of claim 37 wherein said substantially ascending methylphenidate plasma drug concentration is over a time period of about 4 to about 5.5 hours.

47. (new) The method of claim 37 wherein said substantially ascending methylphenidate plasma drug concentration is over a time period of about 5.5 to about 8 hours.

48. (new) The method of claim 37 wherein said substantially ascending methylphenidate plasma drug concentration is over a time period of about 5.5 to about 9.5 hours.

B-  
cancel  
49. (new) A method for treating Attention-Deficit Disorder or Attention-Deficit Hyperactivity Disorder in a patient, wherein the method comprises administering a pharmaceutically acceptable composition comprising 100 ng to 500 mg of methylphenidate and a pharmaceutically acceptable carrier to said patient in a manner that achieves a substantially ascending methylphenidate plasma drug concentration over a time period of about 8 hours following said administration.

50. (new) A method for treating Attention-Deficit Disorder or Attention-Deficit Hyperactivity Disorder in a patient, wherein the method comprises administering a pharmaceutically acceptable composition comprising 100 ng to 500 mg of methylphenidate and a pharmaceutically acceptable carrier to said patient in a manner that achieves a substantially ascending methylphenidate plasma drug concentration over a time period of about 9.5 hours following said administration.